drugset
drugset / Trial / NCT07212322

A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases

NCT07212322 ↗

Not yet recruiting 24 enrolled Institute of Hematology & Blood Diseases Hospital, China
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of CD19 UCAR-T cell therapy in Subjects with autoimmune diseases.

Timeline

Start
2026-01-30
Primary completion
2027-05-20
Completion
2027-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject CD19 UCARTcells Cell therapy — —

Indications

Sjogren syndrome anti-neutrophil cytoplasmic antibody-associated vasculitis antiphospholipid syndrome autoimmune thrombocytopenia idiopathic inflammatory myopathy systemic lupus erythematosus systemic sclerosis